Candesartan Treatment Study

This study assesses the safety and tolerability of Candesartan as an adjunctive treatment of bipolar depression. All patients will receive the study drug for four weeks and a placebo for four weeks. Neither the patients nor the study team will know if the patient received the study drug or the placebo first.

Bipolar patients in a depressive episode will be randomly assigned to undergo two consecutive 4-week treatment periods with Candesartan and placebo. At the beginning of each treatment-period participants will complete a resting-state functional MRI scan. Patients will be seen weekly, and their mood will be assessed with interviews and questionnaires.

We are currently recruiting:

• Adults, ages 18-65
• Receiving treatment for bipolar disorder
• Currently experiencing symptoms of depression

Compensation: Yes

Contact:
utmooddisorders@uth.tmc.edu
713-486-2627
NCT04430959

Take the study survey here.